Diazabicyclic aryl derivatives and their medical use
    101.
    发明授权
    Diazabicyclic aryl derivatives and their medical use 失效
    二氮杂双环芳基衍生物及其医疗用途

    公开(公告)号:US07750011B2

    公开(公告)日:2010-07-06

    申请号:US11884345

    申请日:2006-02-13

    CPC分类号: C07D487/08

    摘要: This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

    摘要翻译: 本发明涉及在尼古丁乙酰胆碱受体和单胺受体和转运蛋白的调节剂中被发现是胆碱能配体的新的二氮杂双环芳基衍生物。 由于其药理学特征,本发明的化合物可用于治疗与中枢神经系统(CNS),周围神经系统(PNS),疾病或病症相关的胆碱能系统相关的疾病或障碍 平滑肌肉收缩,内分泌疾病或病症,与神经变性相关的疾病或病症,与由化学物质的滥用终止引起的炎症,疼痛和戒断症状相关的疾病或病症。

    3-heteroaryl-3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists
    103.
    发明授权
    3-heteroaryl-3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists 有权
    3-杂芳基-3,9-二氮杂双环[3.3.1]壬烷衍生物作为烟碱乙酰胆碱受体激动剂

    公开(公告)号:US07687523B2

    公开(公告)日:2010-03-30

    申请号:US12087004

    申请日:2007-02-09

    IPC分类号: A61K31/44

    CPC分类号: C07D471/08

    摘要: Compounds of the class 3,9-diaza-bicyclo [3.3.1]nonane derivatives. The compounds correspond to structural Formula (I): wherein Ra is hydrogen or optionally substituted alkyl and Rb is a monocyclic heteroaryl group. The compounds are useful in the treatment, prevention, or alleviation of diseases or disorders or conditions that are responsive to modulation of nicotinic acetylcholine receptors, including cognitive disorders, Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, Bipolar Disorder, obsessive compulsive disorders (OCD), narcolepsy, senile dementia, autism, Parkinson'disease, Amyotrophic Lateral Sclerosis, epilepsy, and diabetic neuropathy.

    摘要翻译: 3,9-二氮杂双环[3.3.1]壬烷衍生物的化合物。 化合物对应于结构式(I):其中R a是氢或任选取代的烷基,R b是单环杂芳基。 这些化合物可用于治疗,预防或缓解对烟碱乙酰胆碱受体调节,包括认知障碍,阿尔茨海默病,注意力缺陷多动障碍(ADHD),Tourette综合征,双相障碍,强迫症的疾病或病症或病症 强迫症(OCD),发作性睡病,老年痴呆,自闭症,帕金森病,肌萎缩性侧索硬化,癫痫和糖尿病性神经病变。

    Diazabicyclic aryl derivatives as cholinergy ligands
    105.
    发明授权
    Diazabicyclic aryl derivatives as cholinergy ligands 失效
    二氮杂双环芳基衍生物作为胆碱能配体

    公开(公告)号:US07612074B2

    公开(公告)日:2009-11-03

    申请号:US11663967

    申请日:2005-11-29

    IPC分类号: A61K31/497

    CPC分类号: C07D487/08

    摘要: This invention relates to novel diazabicyclic aryl compounds of the formula wherein: R′ represents hydrogen or alkyl; A represents an aromatic monocyclic or bicyclic carbocyclic or heterocyclic; and is hydrogen or a subsituent as defined in the specification. The compounds are cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. The compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

    摘要翻译: 本发明涉及下式的新的二氮杂双环芳基化合物:其中:R'表示氢或烷基; A表示芳族单环或双环碳环或杂环; 并且是如本说明书中定义的氢或取代基。 这些化合物是烟碱乙酰胆碱受体的胆碱能配体和单胺受体和转运蛋白的调节剂。 本发明的化合物可用于治疗与中枢神经系统(CNS),周围神经系统(PNS)的胆碱能系统,与平滑肌收缩有关的疾病或病症的疾病或病症多种化的疾病或病症, 内分泌疾病或病症,与神经变性相关的疾病或病症,与由化学物质的滥用终止引起的炎症,疼痛和戒断症状有关的疾病或病症。

    Diazabicycylic aryl derivatives and their medical use
    108.
    发明授权
    Diazabicycylic aryl derivatives and their medical use 失效
    二氮杂双环芳基衍生物及其医疗用途

    公开(公告)号:US08173658B2

    公开(公告)日:2012-05-08

    申请号:US12093655

    申请日:2006-12-05

    CPC分类号: C07D471/08

    摘要: This invention relates to novel diazabicyclic aryl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

    摘要翻译: 本发明涉及新的二氮杂双环芳基衍生物,其被发现是烟碱乙酰胆碱受体的胆碱能配体和单胺受体和转运蛋白的调节剂。 由于其药理学特征,本发明的化合物可用于治疗与中枢神经系统(CNS),周围神经系统(PNS),疾病或病症相关的胆碱能系统相关的疾病或障碍 平滑肌肉收缩,内分泌疾病或病症,与神经变性相关的疾病或病症,与由化学物质的滥用终止引起的炎症,疼痛和戒断症状相关的疾病或病症。

    Oxadiazole derivatives and their medical use
    109.
    发明授权
    Oxadiazole derivatives and their medical use 有权
    恶二唑衍生物及其医疗用途

    公开(公告)号:US08017631B2

    公开(公告)日:2011-09-13

    申请号:US11919146

    申请日:2006-04-24

    IPC分类号: A61K31/4245 C07D413/04

    摘要: This invention relates to novel oxadiazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

    摘要翻译: 本发明涉及新的恶二唑衍生物,其被发现是烟碱乙酰胆碱受体的调节剂。 由于其药理学特征,本发明的化合物可用于治疗与中枢神经系统(CNS),周围神经系统(PNS),疾病或病症相关的胆碱能系统相关的疾病或障碍 平滑肌肉收缩,内分泌疾病或病症,与神经变性相关的疾病或病症,与由化学物质的滥用终止引起的炎症,疼痛和戒断症状相关的疾病或病症。